Compare Stocks → AI to Meet the Same Fate as EVs? (From Porter & Company) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AVDLNASDAQ:CMPSNASDAQ:ESPRNASDAQ:GHRS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVDLAvadel Pharmaceuticals$16.72-0.7%$14.81$8.00▼$17.47$1.51B1.561.29 million shs253,378 shsCMPSCOMPASS Pathways$8.40-11.6%$10.34$5.01▼$12.75$520.30M2.52696,205 shs2.12 million shsESPREsperion Therapeutics$2.65+1.1%$2.37$0.70▼$3.34$490.38M0.826.35 million shs4.13 million shsGHRSGH Research$10.61-0.9%$8.39$5.05▼$14.64$552.04M0.79141,359 shs27,743 shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVDLAvadel Pharmaceuticals+3.69%+1.63%+29.64%+15.42%+83.24%CMPSCOMPASS Pathways+2.04%-2.86%-11.05%+4.74%-7.14%ESPREsperion Therapeutics-2.96%+19.63%-0.38%-14.94%+48.86%GHRSGH Research-3.43%-2.64%+33.37%+93.32%+42.99%AI to Meet the Same Fate as EVs? (Ad)When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVDLAvadel Pharmaceuticals3.7845 of 5 stars4.52.00.00.03.43.30.6CMPSCOMPASS Pathways2.9171 of 5 stars3.53.00.00.03.63.30.0ESPREsperion Therapeutics3.7374 of 5 stars3.22.00.03.92.90.80.6GHRSGH Research2.1882 of 5 stars3.52.00.00.03.42.50.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVDLAvadel Pharmaceuticals3.00Buy$22.5735.00% UpsideCMPSCOMPASS Pathways3.00Buy$49.00483.33% UpsideESPREsperion Therapeutics2.40Hold$9.33252.20% UpsideGHRSGH Research3.00Buy$39.50272.29% UpsideCurrent Analyst RatingsLatest GHRS, AVDL, CMPS, and ESPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/25/2024ESPREsperion TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.003/25/2024ESPREsperion TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.003/5/2024AVDLAvadel PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.003/5/2024AVDLAvadel PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$18.00 ➝ $23.003/5/2024AVDLAvadel PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$27.00 ➝ $29.003/5/2024AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $25.003/5/2024AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.003/4/2024GHRSGH ResearchHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.003/1/2024CMPSCOMPASS PathwaysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$120.003/1/2024GHRSGH ResearchJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$50.00 ➝ $39.002/28/2024ESPREsperion TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $16.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVDLAvadel Pharmaceuticals$27.96M54.17N/AN/A$0.98 per share17.06CMPSCOMPASS PathwaysN/AN/AN/AN/A$3.65 per shareN/AESPREsperion Therapeutics$116.33M4.22N/AN/A($3.85) per share-0.69GHRSGH ResearchN/AN/AN/AN/A$4.94 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVDLAvadel Pharmaceuticals-$160.28M-$2.04N/A20.14N/AN/A-198.06%-84.51%5/2/2024 (Estimated)CMPSCOMPASS Pathways-$118.46M-$2.39N/AN/AN/AN/A-58.72%-49.46%5/9/2024 (Estimated)ESPREsperion Therapeutics-$209.25M-$2.12N/A7.79N/A-179.87%N/A-91.62%5/14/2024 (Estimated)GHRSGH Research-$35.59M-$0.68N/AN/AN/AN/A-15.48%-15.01%5/9/2024 (Estimated)Latest GHRS, AVDL, CMPS, and ESPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/4/2024Q4 2023AVDLAvadel Pharmaceuticals-$0.28-$0.32-$0.04-$0.29$17.41 million$19.45 million 2/29/2024Q4 2023CMPSCOMPASS Pathways-$0.37-$0.53-$0.16-$0.53N/AN/A2/29/2024Q4 2023GHRSGH Research-$0.20-$0.21-$0.01-$0.21N/AN/A2/27/202412/31/2023ESPREsperion Therapeutics-$0.53-$0.50+$0.03-$0.50$26.84 million$32.25 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/ACMPSCOMPASS PathwaysN/AN/AN/AN/AN/AESPREsperion TherapeuticsN/AN/AN/AN/AN/AGHRSGH ResearchN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVDLAvadel PharmaceuticalsN/A3.643.36CMPSCOMPASS Pathways0.1413.3313.33ESPREsperion TherapeuticsN/A1.290.87GHRSGH ResearchN/A24.4924.49OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVDLAvadel Pharmaceuticals69.19%CMPSCOMPASS Pathways46.19%ESPREsperion Therapeutics47.39%GHRSGH Research56.90%Insider OwnershipCompanyInsider OwnershipAVDLAvadel Pharmaceuticals4.00%CMPSCOMPASS Pathways23.99%ESPREsperion Therapeutics0.60%GHRSGH Research41.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAVDLAvadel Pharmaceuticals15490.58 million86.95 millionOptionableCMPSCOMPASS Pathways18661.94 million47.08 millionOptionableESPREsperion Therapeutics240185.05 million183.94 millionOptionableGHRSGH Research3252.03 million30.38 millionOptionableGHRS, AVDL, CMPS, and ESPR HeadlinesSourceHeadlineGH Research (NASDAQ:GHRS) Trading Down 4.4%marketbeat.com - March 21 at 6:43 PMGH Research (NASDAQ:GHRS) Sees Strong Trading Volumemarketbeat.com - March 20 at 4:31 PMGeneral Hospital Video Preview: Misdirections, Maladies, and Misdiagnosesyahoo.com - March 17 at 8:58 AMGE HealthCare & Mass General Brigham Have a Plan to Accelerate Their AI Researchmedcitynews.com - March 15 at 9:14 AMGeneral Hospital Video Preview: Catastrophic Thoughts Plague Jason and Sonnyyahoo.com - March 15 at 9:14 AMThe General Hospital Coming Out Storyline Nobody Saw Comingyahoo.com - March 15 at 9:14 AMGE HealthCare, Mass General Brigham ramp up AI researchmodernhealthcare.com - March 13 at 10:59 PMGH Research (NASDAQ:GHRS) Trading 7.9% Higher marketbeat.com - March 13 at 2:16 PMHow Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28%zacks.com - March 5 at 10:55 AMBuy Rating for GH Research: Promising Clinical Trials and Strategic Intellectual Property Advancesmarkets.businessinsider.com - March 4 at 8:36 PMBuy Rating Justified by GH Research’s Promising Clinical Trials and Strong Financial Healthmarkets.businessinsider.com - March 1 at 9:58 AMGH Research: This European Biotech Company Reports Full Year 2023 Financial Results And Business Updatesmsn.com - March 1 at 12:07 AMGH Research Reports Full Year 2023 Financial Results and Provides Business Updatesglobenewswire.com - February 29 at 7:00 AMGH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depressionfinance.yahoo.com - January 18 at 5:17 PMCan GH Research PLC (GHRS) Climb 488.72% to Reach the Level Wall Street Analysts Expect?finance.yahoo.com - January 16 at 3:04 PMGeneral Hospital Season 61: How Many Episodes & When Do New Episodes Come Out?yahoo.com - January 16 at 10:03 AMGeneral Hospital Season 61 Streaming: Watch & Stream Online via Huluyahoo.com - December 26 at 6:22 PMWe're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash Wiselyfinance.yahoo.com - December 25 at 9:30 AMThese Four Stocks Tap into the Exploding Psychedelic Treatment Marketnasdaq.com - December 20 at 11:19 PMPsyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And Moremsn.com - November 24 at 1:44 PMAnalysts Offer Insights on Technology Companies: Inuvo (INUV) and GH Research (GHRS)markets.businessinsider.com - November 11 at 4:48 AMGH Research Earns ‘Buy’ Rating: Promising Progress, Proactive Approach, and Solid Financial Standingmarkets.businessinsider.com - November 10 at 5:28 PMGH Research PLC: GH Research Reports Third Quarter Financial Results and Provides Business Updatesfinanznachrichten.de - November 10 at 7:27 AMGH Research Reports Third Quarter Financial Results and Provides Business Updatesfinance.yahoo.com - November 9 at 9:27 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAvadel PharmaceuticalsNASDAQ:AVDLAvadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.COMPASS PathwaysNASDAQ:CMPSCOMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Esperion TherapeuticsNASDAQ:ESPREsperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.GH ResearchNASDAQ:GHRSGH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an intravenous mebufotenin product candidate; and GH003, an intranasal mebufotenin product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.